Erica Moretti

Erica Moretti

Auto-generated profile, based on publicly available information

Erica Moretti

Sandro Pitigliani Medical Oncology Department, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2011 in Cancer
Verified
Journal Article
Open access
PDF file
EJEun‐Jung Jung
Eun‐Jung Jung
LSLibero Santarpia
Libero Santarpia
JKJuyeon Kim
Juyeon Kim
FEFrancisco J Esteva
Francisco J Esteva
EMErica Moretti
Erica Moretti
George CalinGeorge Calin
George Calin
BACKGROUND: Trastuzumab is part of the standard treatment for patients with human epidermal growth factor receptor 2 (HER‐2)‐positive breast cancer, but not all patients respond to trastuzumab. Altered microRNA (miR) expression levels in cancer cells have been correlated with prognosis and response to chemotherapy. The authors of this report hypothesized that altered miR expression levels in plasma are associated with sensitivity to trastuzumab in patients with HER‐2 positive breast cancer.METHODS: Quantitative reverse transcriptase‐polymerase chain reaction was used to analyze plasma samples, including samples from patients with breast cancer who were enrolled in a clinical trial of neoadjuvant trastuzumab‐based chemotherapy. Expression levels of miR‐210, miR‐21, miR‐29a, and miR‐126 were analyzed according to the type of response (pathologic complete response [n = 18] vs residual disease [n = 11]). MicroRNA expression levels also were compared in trastuzumab‐sensitive and trastuzumab‐resistant breast cancer cells derived from BT474 cells and in an independent set of preoperative plasma samples (n = 39) and postoperative plasma samples (n = 30) from 43 breast cancer patients who did not receive any treatment.RESULTS: At baseline before patients received neoadjuvant chemotherapy combined with trastuzumab, circulating miR‐210 levels were significantly higher in those who had residual disease than in those who achieved a pathologic complete response (P = .0359). The mean expression ratio for miR‐210 was significantly higher in trastuzumab‐resistant BT474 cells, and miR‐210 expression was significantly higher before surgery than after surgery (P = .0297) and in patients whose cancer metastasized to the lymph nodes (P = .0030).CONCLUSIONS: Circulating miR‐210 levels were associated with trastuzumab sensitivity, tumor presence, and lymph node metastases. These results suggest that plasma miR‐210 may be used to predict and perhaps monitor response to therapies that contain trastuzumab. Cancer 2011;. © 2011 American Cancer Society.

1 August 2013 in Cancer Treatment Reviews
Verified
Journal Article
Closed access
NTNatalie Turner
Natalie Turner
EMErica Moretti
Erica Moretti
OSOlimpia Siclari
Olimpia Siclari
IMIlenia Migliaccio
Ilenia Migliaccio
LSLibero Santarpia
Libero Santarpia
ALAngelo Di Leo
Angelo Di Leo

1 December 2009 in Cancer Treatment Reviews
Verified
Journal Article
Closed access
COCatherine Oakman
Catherine Oakman
EMErica Moretti
Erica Moretti
FGFrancesca Galardi
Francesca Galardi
LSLibero Santarpia
Libero Santarpia
ALAngelo Di Leo
Angelo Di Leo

1 June 2009 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
Laura BiganzoliLaura Biganzoli
Laura Biganzoli
SLSara Licitra
Sara Licitra
EMErica Moretti
Erica Moretti
MPMarta Pestrin
Marta Pestrin
EZElena Zafarana
Elena Zafarana
ALAngelo Di Leo
Angelo Di Leo

1 November 2008 in Journal of Clinical Oncology
Verified
Journal Article
Open access
ALAngelo Di Leo
Angelo Di Leo
EMErica Moretti
Erica Moretti

30 September 2011 in European Journal of Cancer
Verified
Journal Article
Closed access
PDF file
COCatherine Oakman
Catherine Oakman
EMErica Moretti
Erica Moretti
GPGiulia Pacini
Giulia Pacini
LSLibero Santarpia
Libero Santarpia
ALAngelo Di Leo
Angelo Di Leo